{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:43:22Z","timestamp":1790451802841,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008623","name":"Broad Stem Cell Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Biotechnology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.copbio.2018.11.016","type":"journal-article","created":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T18:17:35Z","timestamp":1546107455000},"page":"39-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Gene therapy for blood diseases"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-6087","authenticated-orcid":false,"given":"Donald B","family":"Kohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.copbio.2018.11.016_bib0005","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.copbio.2018.11.016_bib0010","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev-biochem-060713-035418","article-title":"Genome engineering with targetable nucleases","volume":"83","author":"Carroll","year":"2014","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.copbio.2018.11.016_bib0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.hoc.2017.06.011","article-title":"Gene therapy for hemophilia","volume":"31","author":"Nathwani","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.copbio.2018.11.016_bib0020","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.tig.2018.05.004","article-title":"Gene editing on center stage","volume":"34","author":"Bak","year":"2018","journal-title":"Trends Genet"},{"key":"10.1016\/j.copbio.2018.11.016_bib0025","first-page":"1","article-title":"SPK-9001: adeno-associated virus mediated gene transfer for hemophilia B - sustained fix activity, persistent endogenous prophylaxis and improved quality of life at one year and beyond","volume":"26","author":"George","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.copbio.2018.11.016_bib0030","first-page":"458","article-title":"Therapeutic factor IX (FIX) activity after single treatment with AMT-060 (AAV5-FIX) in hemophilia B patients with pre-existing anti-AAV5 humoral immunity","volume":"26","author":"Majowicz","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.copbio.2018.11.016_sbref0035","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.copbio.2018.11.016_bib0040","first-page":"163","article-title":"SPK-8011: preliminary results from a phase 1\/2 trial of investigational gene therapy for hemophilia confirm transgene derived increases in FVIII activity that are persistent and stable beyond eight months","volume":"26","author":"Sullivan","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.copbio.2018.11.016_bib0045","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11095-007-9431-0","article-title":"Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer","volume":"25","author":"Kwon","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.copbio.2018.11.016_bib0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ymthe.2017.09.021","article-title":"Bioengineered AAV capsids with combined high human liver transduction in vivo and unique humoral seroreactivity","volume":"26","author":"Paulk","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.copbio.2018.11.016_sbref0055","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2018.11.016_bib0060","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.copbio.2018.11.016_bib0065","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1513\/AnnalsATS.201506-344KV","article-title":"Gene therapy for alpha-1 antitrypsin deficiency lung disease","volume":"13","author":"Chiuchiolo","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.copbio.2018.11.016_bib0070","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/hum.2011.053","article-title":"Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing \u03b11-antitrypsin: interim results","volume":"22","author":"Flotte","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.copbio.2018.11.016_bib0075","series-title":"Man Receives First In Vivo Gene-Editing Therapy","author":"Grens","year":"2017"},{"key":"10.1016\/j.copbio.2018.11.016_bib0080","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.copbio.2018.11.016_bib0085","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2018-03-837609","article-title":"Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma","volume":"132","author":"Svoboda","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.copbio.2018.11.016_bib0090","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2018.11.016_bib0095","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.bbmt.2017.12.789","article-title":"Building a safer and faster CAR: seatbelts, airbags, and CRISPR","volume":"24","author":"Perales","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.copbio.2018.11.016_bib0100","doi-asserted-by":"crossref","first-page":"215ra","DOI":"10.1126\/scitranslmed.3007320","article-title":"CD4+T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer","volume":"5","author":"Passerini","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.copbio.2018.11.016_bib0105","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2015.12.1311","article-title":"Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes","volume":"137","author":"Naik","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.copbio.2018.11.016_bib0110","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.copbio.2018.11.016_bib0115","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.hoc.2017.06.006","article-title":"Historical perspective on the current renaissance for hematopoietic stem cell gene therapy","volume":"31","author":"Kohn","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.copbio.2018.11.016_bib0120","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/hum.2017.175","article-title":"Twenty-five years of gene therapy for ADA-SCID: from bubble babies to an approved drug","volume":"28","author":"Ferrua","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.copbio.2018.11.016_bib0125","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified \u03b3-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2018.11.016_bib0130","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1126\/science.aah6192","article-title":"Lentiviral vectors, two decades later","volume":"353","author":"Naldini","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.copbio.2018.11.016_bib0135","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.copbio.2018.11.016_sbref0140","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2018.11.016_bib0145","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.copbio.2018.11.016_bib0150","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.copbio.2018.11.016_bib0155","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.copbio.2018.11.016_sbref0160","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent \u03b2-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2018.11.016_bib0165","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.hoc.2017.06.010","article-title":"Gene therapy approaches to hemoglobinopathies","volume":"31","author":"Ferrari","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.copbio.2018.11.016_bib0170","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2018.11.016_bib0175","doi-asserted-by":"crossref","first-page":"335ra","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.copbio.2018.11.016_bib0180","first-page":"342","article-title":"Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): analysis of cases enrolled in protocols of the Primary Immune Deficiency Treatment Consortium (PIDTC)","volume":"38","author":"Kuo","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.copbio.2018.11.016_bib0185","first-page":"364","article-title":"Gene therapy for adenosine deaminase-deficient severe combined immunodeficiency (ADA SCID) with a lentiviral vector","volume":"38","author":"Kohn","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.copbio.2018.11.016_bib0190","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1093\/nar\/gkv1121","article-title":"Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery","volume":"44","author":"Wang","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.copbio.2018.11.016_bib0195","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2018.11.016_bib0200","doi-asserted-by":"crossref","first-page":"16067","DOI":"10.1038\/mtm.2016.67","article-title":"Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem\/progenitor cells","volume":"3","author":"DiGiusto","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.copbio.2018.11.016_sbref0205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.copbio.2018.11.016_bib0210","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","article-title":"Reprogramming human T cell function and specificity with non-viral genome targeting","volume":"559","author":"Roth","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.copbio.2018.11.016_bib0215","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2017.05.023","article-title":"Improving gene therapy efficiency through the enrichment of human hematopoietic stem cells","volume":"25","author":"Masiuk","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.copbio.2018.11.016_bib0220","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.stemcr.2017.02.010","article-title":"Efficient ex vivo engineering and expansion of highly purified human hematopoietic stem and progenitor cell populations for gene therapy","volume":"8","author":"Zonari","year":"2017","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.copbio.2018.11.016_bib0225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1145","article-title":"A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates","volume":"9","author":"Radtke","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.copbio.2018.11.016_bib0230","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/mt.2014.193","article-title":"Cyclosporin A and rapamycin relieve distinct lentiviral restriction blocks in hematopoietic stem and progenitor cells","volume":"23","author":"Petrillo","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.copbio.2018.11.016_bib0235","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.omtm.2018.04.001","article-title":"Staurosporine increases lentiviral vector transduction efficiency of human hematopoietic stem and progenitor cells","volume":"9","author":"Lewis","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.copbio.2018.11.016_bib0240","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymthe.2017.09.025","article-title":"Prostaglandin E2 increases lentiviral vector transduction efficiency of adult human hematopoietic stem and progenitor cells","volume":"26","author":"Heffner","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.copbio.2018.11.016_bib0245","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/hgtb.2017.085","article-title":"Improving lentiviral transduction of CD34+ hematopoietic stem and progenitor cells","volume":"29","author":"Hauber","year":"2018","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.copbio.2018.11.016_bib0250","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2008-11-191049","article-title":"Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection","volume":"113","author":"Throm","year":"2009","journal-title":"Blood"}],"container-title":["Current Opinion in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958166918302088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958166918302088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:03:47Z","timestamp":1760691827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0958166918302088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":50,"alternative-id":["S0958166918302088"],"URL":"https:\/\/doi.org\/10.1016\/j.copbio.2018.11.016","relation":{},"ISSN":["0958-1669"],"issn-type":[{"value":"0958-1669","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for blood diseases","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.copbio.2018.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}